arcutis
completes
enrollment
phase
study
evaluating
chronic
hand
eczema
nasdaq
arqt
potent
highly
selective
topical
inhibitor
offering
potential
safety
advantages
less
selective
jak
inhibitors
hand
eczema
common
skin
disease
affecting
hands
impacting
million
americans
topline
data
anticipated
westlake
village
globe
newswire
arcutis
biotherapeutics
nasdaq
arqt
medical
dermatology
company
developing
innovative
treatments
patients
dermatological
diseases
conditions
today
announced
completed
enrollment
phase
study
potent
highly
selective
topical
small
molecule
inhibitor
janus
kinase
type
adult
patients
chronic
hand
eczema
arcutis
updated
projections
anticipates
announcing
topline
data
trial
pleased
speed
trial
enrolled
underscoring
high
unmet
need
new
treatments
treat
chronic
skin
disease
cause
significant
skin
irritation
discomfort
negative
impact
patient
quality
life
said
patrick
burnett
faad
arcutis
chief
medical
officer
eight
million
people
suffer
hand
eczema
patients
often
make
drug
efficacy
safety
tolerability
current
available
treatments
demonstrated
robust
potency
high
selectivity
thereby
giving
potential
deliver
efficacy
without
causing
side
effects
typical
less
selective
jak
inhibitors
given
believe
potential
reduce
need
compromise
safety
april
arcutis
began
phase
portion
phase
study
assess
safety
tolerability
pharmacokinetics
daily
application
cream
hands
two
weeks
seven
subjects
chronic
hand
eczema
july
company
began
phase
portion
study
assess
safety
efficacy
cream
daily
cream
daily
twice
daily
versus
vehicle
applied
daily
twice
daily
weeks
patients
chronic
hand
eczema
enrollment
phase
portion
complete
subjects
company
expects
report
topline
data
hand
eczema
hand
eczema
common
inflammatory
skin
disease
prevalence
estimated
population
common
skin
disease
affecting
hands
symptoms
hand
eczema
vary
include
redness
fluid
filled
blisters
bumps
scaling
cracking
itching
pain
occurring
hands
may
occur
various
forms
incorporating
dyshidrotic
eczema
immune
disease
possibly
related
atopic
dermatitis
irritant
contact
dermatitis
hands
may
caused
occupational
irritants
allergic
contact
dermatitis
hands
caused
allergic
reaction
atopic
hand
dermatitis
atopic
dermatitis
occurring
hands
hyperkeratotic
hand
dermatitis
thickened
scaly
red
plaques
similar
psoriasis
hands
impact
hand
eczema
patients
significant
leading
work
absences
disability
social
stigmatization
psychosocial
distress
potent
highly
selective
topical
small
molecule
inhibitor
janus
kinase
type
many
inflammatory
cytokines
signaling
molecules
rely
jak
pathway
specifically
plays
central
role
immune
system
function
inhibition
shown
treat
range
inflammatory
diseases
including
rheumatoid
arthritis
crohn
disease
atopic
dermatitis
company
believes
due
high
selectivity
potential
effectively
treat
inflammatory
diseases
without
causing
hematopoietic
adverse
effects
typically
associated
inhibition
arcutis
exclusively
licensed
active
pharmaceutical
ingredient
topical
dermatological
uses
united
states
europe
japan
canada
jiangsu
hengrui
medicine
china
hengrui
completed
phase
study
rheumatoid
arthritis
used
active
pharmaceutical
ingredient
dosed
orally
results
confirmed
active
pharmaceutical
ingredient
highly
potent
inhibitor
based
drug
impact
rheumatoid
arthritis
generally
well
tolerated
exposures
well
expected
topical
administration
patients
chronic
hand
eczema
reistone
biopharma
subsidiary
hengrui
also
studying
oral
formulation
potential
treatment
alopecia
areata
crohn
disease
ulcerative
colitis
atopic
dermatitis
arcutis
bioscience
applied
skin
arcutis
biotherapeutics
nasdaq
arqt
medical
dermatology
company
developing
innovative
treatments
patients
dermatological
diseases
conditions
company
leveraging
recent
advances
immunology
inflammation
develop
differentiated
therapies
biologically
validated
targets
solve
persistent
treatment
challenges
serious
diseases
skin
arcutis
robust
pipeline
includes
four
novel
drug
candidates
currently
development
range
inflammatory
dermatological
conditions
company
lead
product
candidate
topical
roflumilast
potential
revitalize
standard
care
plaque
psoriasis
atopic
dermatitis
scalp
psoriasis
seborrheic
dermatitis
information
visit
follow
company
linkedin
twitter
forward
looking
statements
press
release
contains
statements
including
among
others
statements
regarding
potential
treat
hand
eczema
without
causing
adverse
effects
associated
jak
inhibitors
anticipated
timing
topline
data
phase
portion
study
statements
involve
substantial
known
unknown
risks
uncertainties
factors
may
cause
actual
results
levels
activity
performance
achievements
materially
different
information
expressed
implied
statements
place
undue
reliance
statements
risks
uncertainties
may
cause
actual
results
differ
include
risks
inherent
clinical
development
process
regulatory
approval
process
timing
regulatory
filings
ability
defend
intellectual
property
description
risks
uncertainties
applicable
business
see
risk
factors
section
form
filed
securities
exchange
commission
sec
august
well
subsequent
filings
sec
undertake
obligation
revise
update
information
herein
reflect
events
circumstances
future
even
new
information
becomes
available
investors
media
heather
rowe
armstrong
vice
president
investor
relations
corporate
communications
harmstrong
ext
